A team led by researchers at Sangamo Therapeutics has shown the first, direct, demonstration of allele-selective transcriptional repression at the huntingtin locus. This opens up a novel therapeutic approach to targeting the gene responsible for Huntington's disease.
Ultivue, a developer of tissue biomarker identification and quantification assays for translational and pathology research labs, has completed a $22 million Series C financing.
Ebola, Zika, and other terrifying diseases are the stuff of “hot zones,” but they inspire cool technologies such as mRNA vaccines, neutralizing antibodies, and designer DNA immunotherapies.
Labs participating in the Cancer Moonshot are using the latest mass spec techniques to streamline proteomic workflows and advance biomarker development.
A scientist in biologics discovery or cell line development, working at peak efficiency, typically can screen between 5000 and 10,000 antibody-secreting cells per day. What if we could increase daily output to 40 million? Imagine what could happen.
Researchers used a combination of single-cell RNA sequencing and two-photon calcium imaging to identify obesity-related changes to glutamatergic neurons in the lateral hypothalamic area of the brain, which in mice fed a a normal diet, functionally put the brakes on overeating. In animals fed a high-fat diet, the neurons were modified in a way that disrupted the natural feeding suppression system to promote overeating and obesity.
Studies in cultured neurons and mouse models suggest have found that using an anticancer drug candidate to inhibit an enzyme that acts downstream of existing challenging Alzheimer’s disease targets can help to protect neurons from amyloid beta-induced dendritic spine degeneration.
Bristol-Myers Squibb (BMS) said today it will divest itself of the psoriasis drug Otezla® (apremilast) as part of its planned $74 billion acquisition of Celgene, in order to address what it called “concerns” raised by the U.S. Federal Trade Commission concerns about the blockbuster deal.
Using mouse models of B-cell lymphoma, researchers added a histone deacetylase inhibitor that sensitized cancers to anti-PD1 therapy.